In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen

Juan   Enriquez-Cabot; Gary P. Pisano; Gaye  Bok

Case | HBS Case Collection | April 2002

In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen

by Juan Enriquez-Cabot, Gary P. Pisano and Gaye Bok

Abstract

Biogen is a successful biotech company facing a critical juncture. CEO John Mullen ponders how technological changes introduced into the research function will shape larger corporate decisions. This world in which biotechnology companies operated had changed dramatically over the past few years. Parts of biology were rapidly evolving from being an individualistic, wet lab, bench-science driven field toward one where scientists manipulated huge amounts of data and divided up research steps into a factorylike production process. At the same time, the cost of developing a drug and bringing it to market had ballooned, from an estimated $231 million in 1991 to $802 million in 2000. Biogen was conservative in adopting new genomics tools. This case describes how the company decided to bring in house the latest genomics in silico tools and applied them to the discovery and research phase for drug development. The company also then restructured its research strategy. As the new tools and early-phase research began to bear fruit, Mullen realized that they implied significant changes down the road for other parts of Biogen.

Keywords: Change; Decisions; Product Development; Research and Development; Expansion; Technology; Biotechnology Industry;

Format: Print

30 pages

Educators Purchase

Citation:

Enriquez-Cabot, Juan, Gary P. Pisano, and Gaye Bok. "In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen." Harvard Business School Case 602-122, April 2002.

Creative Construction tackles the myth that larger enterprises are inherently incapable of transformative innovation and are doomed to be disrupted by nimble start-ups. If larger enterprises seem incapable of transformative innovation, it is due to how we design and manage them, rather than anything inherent in their scale. In fact, Creative Construction argues, if used properly, scale can be an asset, rather than a liability, when it comes to innovation. However, to leverage the advantages of scale for innovation, companies need the right combination of strategy, systems, and culture. Based on more than three decades of the Pisano's research, teaching, and experience, Creative Construction offers a set of principles that will lead readers to rethink many long-held beliefs about innovation.

Innovative cultures are generally depicted as pretty fun. They’re characterized by a tolerance for failure and a willingness to experiment. They’re seen as being psychologically safe, highly collaborative, and nonhierarchical. And research suggests that these behaviors translate into better innovative performance. But despite the fact that innovative cultures are desirable, and that most leaders claim to understand what they entail, they are hard to create and sustain. That’s because the easy-to-like behaviors that get so much attention are only one side of the coin. They must be counterbalanced by some tougher and frankly less fun behaviors: an intolerance for incompetence, rigorous discipline, brutal candor, a high level of individual accountability, and strong leadership. Unless the tensions created by this paradox are carefully managed, attempts to create an innovative culture will fail.

Faculty & Research

In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen

Abstract

Citation:

About the Author

More from the Author